NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route
Article in Cancer Cell International (February 2024)
The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.
Article in Cancer Cell International (February 2024)
Article in Frontiers in Immunology (November 2023)
Article in Scientific Reports (May 2023)